McKesson Corp

MCK

Equity

ISIN null / Valor 991041

New York Stock Exchange, Inc (2025-11-21)

USD 866.03+1.95%

McKesson Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

McKesson Corporation is a leading healthcare services and pharmaceutical distribution company operating both in the United States and internationally. The company specializes in delivering a broad range of pharmaceutical products, medical supplies, and equipment to hospitals, pharmacies, and other healthcare providers, ensuring efficient supply chain management and timely access to essential medications. In addition to its distribution network, McKesson offers various healthcare services, including inventory management, technology solutions, and automation tools designed to enhance the operational efficiency of healthcare organizations. By integrating these services with its extensive product offerings, McKesson plays a pivotal role in supporting the infrastructure of the healthcare industry and addressing the evolving challenges faced by healthcare providers today and in the future.

Summarized from source with an LLMView SourceSector: Healthcare

Record Revenue Growth

McKesson achieved a record revenue of $97.8 billion in Q1 2025, marking a 23% increase compared to the same period last year. This growth was primarily driven by the U.S. Pharmaceutical segment, with higher prescription volumes and expanded distribution of oncology and specialty products.

Adjusted Earnings Surge

The company's Adjusted Earnings per Diluted Share rose by 5% to $8.26, attributed to robust operational performance across the business. This improvement was partially offset by a higher tax rate and pre-tax gains from McKesson Ventures’ equity investments in the previous year.

Strategic Acquisitions

McKesson successfully closed the acquisitions of PRISM Vision Holdings and Core Ventures, enhancing its capabilities in Oncology and Specialty solutions. Additionally, the company allocated $3.4 billion of cash towards acquisitions during the quarter, further expanding its market reach.

Guidance for Fiscal 2026

The corporation has raised its fiscal 2026 Adjusted Earnings per Diluted Share guidance to a range of $37.10 to $37.90, up from the previous $36.90 to $37.70. This increase reflects confidence in ongoing strategic initiatives, including the planned sale of its Norwegian businesses.

Shareholder Returns and Cash Flow

In Q1 2025, McKesson returned $671 million to shareholders through $581 million in stock repurchases and $90 million in dividend payments. The company reported a negative Free Cash Flow of $1.1 billion, resulting from $918 million used in operations and $189 million invested in capital expenditures.

Summarized from source with an LLMView Source

Key figures

37.8%1Y

135%3Y

410%5Y

Performance

25.3%1Y

23.5%3Y

23.6%5Y

Volatility